编辑推荐——法国外周动脉疾病血运重建:对实施VOYAGER-PAD的启示
基于法国国家出院数据库的观察性回顾研究纳入2016年1月1日至2019年12月31日因外周动脉疾病行下肢血运重建的180 870例患者,其中90 379例(50.0%)符合VOYAGER-PAD试验标准;符合标准者更年轻、合并症更少、结局更好,但仍有36.0%发生肢体或心血管事件。
要点
- 法国每年约45 000例外周动脉疾病患者接受下肢血运重建。
- 50.0%的血运重建患者符合VOYAGER-PAD试验标准,可考虑双通路抑制治疗。
- 符合标准者随访中36.0%发生肢体或心血管事件,负担仍高。
核心结论
- 外周动脉疾病血运重建及二次事件负担相当大,法国一半的血运重建患者符合双通路抑制治疗条件。
- 符合VOYAGER-PAD标准的患者更年轻、合并症更少且结局更好。
研究设计与样本
- 观察性回顾研究,基于法国国家出院数据库,纳入2016年1月1日至2019年12月31日因外周动脉疾病行下肢血运重建且既往两年内无下肢血运重建的患者。
- 共纳入180 870例患者,平均年龄72.0±12.2岁,女性占30.9%,每年约45 000例接受血运重建。
- 将可获得的VOYAGER-PAD筛选标准应用于研究人群,符合标准者90 379例(50.0%),平均年龄69.8±12.1岁,女性占29.5%。
主要发现
- 研究人群与VOYAGER-PAD合格亚组中,糖尿病分别为33.9%与26.6%,慢性冠心病分别为28.1%与19.9%,肾功能衰竭分别为14.6%与5.7%。
- 研究人群中73.1%接受腔内治疗,VOYAGER-PAD合格亚组中为75.5%。
- 随访超过1年的患者中,研究人群45.4%与VOYAGER-PAD合格亚组36.0%发生肢体或心血管事件。
- 首次事件及院内死亡的中位时间分别为4.8个月与7.8个月,VOYAGER-PAD合格亚组分别为6.7个月与12.9个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The VOYAGER-PAD trial demonstrated the interest in dual pathway inhibition (DPI) (low dose rivaroxaban plus aspirin) to reduce limb and cardiovascular events after revascularisation for peripheral artery disease (PAD), but its applicability in clinical practice has not yet been assessed. This study aimed to assess the number of patients revascularised in France for PAD and to estimate the proportion of those matching the VOYAGER-PAD trial selection criteria. A secondary objective was to examine the prognosis of revascularised patients in a real world setting. METHODS: This observational retrospective study was conducted on the national hospital discharge database and included all patients with PAD who underwent lower extremity revascularisation for PAD (without lower extremity revascularisation in the two years prior to inclusion) from 1 January 2016 to 31 December 2019. Available VOYAGER-PAD selection criteria were then applied to the study population. RESULTS: In total, 180 870 patients were included (mean age 72.0 ± 12.2 years, 30.9% female), with approximately 45 000 patients revascularised annually. Among them, 90 379 (50.0%) matched the VOYAGER-PAD trial criteria (VOYAGER-PAD eligible subgroup; mean age 69.8 ± 12.1 years, 29.5% female). In the study population and the VOYAGER-PAD eligible subgroup, 33.9% and 26.6% of patients had diabetes, 28.1% and 19.9% had chronic coronary artery disease, and 14.6% and 5.7% had renal failure, respectively. Overall, 73.1% of study patients were treated by an endovascular approach (75.5% in the VOYAGER-PAD eligible subgroup). In patients with more than one year of follow up, 45.4% of study patients and 36.0% of the VOYAGER-PAD eligible subgroup experienced a limb or cardiovascular event. The median time until the first event and in hospital death was 4.8 months and 7.8 months, respectively (6.7 months and 12.9 months in the VOYAGER-PAD eligible subgroup). CONCLUSION: The burden of PAD for revascularisation and secondary events is considerable. One half of revascularised patients in France are eligible for DPI therapy. Those patients are younger, with fewer comorbidities, and better outcomes.
引用
- Aboyans V, Morboeuf O, Grenier B, et al. Editor's Choice - Revascularisation for Peripheral Artery Disease in France: Implications for the Implementation of VOYAGER-PAD. Eur J Vasc Endovasc Surg. 2024. PMID: 38316351. doi:10.1016/j.ejvs.2024.01.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。